# Case Report: FIA plus venetoclax in a patient on hemodialysis

## TL;DR

A patient with kidney failure and leukemia successfully responded to a specific chemotherapy regimen.

## Contribution

This case report demonstrates the successful use of FIA plus venetoclax in a hemodialysis-dependent AML patient.

## Key findings

- A 65-year-old female on hemodialysis achieved complete remission with FIA plus venetoclax for AML.
- The regimen was safely administered despite challenges in patients with end-stage renal disease.
- Interdisciplinary coordination was essential for managing pharmacological and logistical barriers.

## Abstract

The safe and effective delivery of curative cytotoxic chemotherapy for acute myeloid leukemia (AML) in patients receiving intermittent hemodialysis (IHD) for end-stage renal disease (ESRD) remains a clinical challenge; pharmacological and logistical barriers necessitate close interdisciplinary coordination. In this case, we report a 65-year-old female patient with chronic ESRD on IHD and newly diagnosed AML who achieved complete remission (CR) after treatment with fludarabine, idarubicin, and cytarabine plus venetoclax (i.e., FIA + venetoclax).